Binx Health, the pioneer in anywhere, anytime testing for women’s health, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its first-of-kind, highly sensitive and specific, molecular point-of-care (POC) diagnostic testing platform, the binx io®. The binx io platform is a rapid, qualitative, fully-automated test, designed to be easy to use, and intended for use in POC or clinical laboratory settings, providing the world’s first sample-to-answer result in about 30 minutes for the detection of chlamydia (CT) and gonorrhea (NG)—the two most tested-for STIs globally. In the Company’s recently completed 1,523-person, multi-center clinical study, 96% of patient samples were processed on the binx io by non-laboratorians in a POC setting.
We are a one-stop shop Healthcare Advisory & Consulting boutique and we help businesses with funding, market access, business strategy, distribution.
AI Alzheimer antibodies Biosimilar Cancer cardiovascular cell therapy CE Mark clinical trial Diagnostics Digital Health Drug Discovery EpiVax' FDA FDA approval funding fundraising HIV Immunogenicity Immunotherapies INVO Bioscience Licensing M&A medical device microbiome Neuro next-gen sequencing NGS PathAI pathology Pepticom peptides pharma PierianDx RNA robots Shape Therapeutics skin software SurgiMab Therapeutics therapies USA VIrology Virus